司来吉林(二烯基)治疗帕金森病的安全性。

文章的细节

引用

复制到剪贴板

海诺宁EH, mylyla V

司来吉林(二烯基)治疗帕金森病的安全性。

毒品杂志1998七月;19(1):11-22。

PubMed ID

9673855 (PubMed视图

］

摘要

司来吉兰单独服用耐受性良好。单药治疗期间最常见的不良事件有失眠、恶心、良性心律失常、头晕和头痛。当与左旋多巴联合使用时，如果左旋多巴的剂量没有充分减少，司来吉兰可增强左旋多巴的典型不良反应。因此，与这种组合相关的最常见的不良反应是恶心、头晕、疲劳、便秘和失眠。在帕金森病的晚期，当残疾出现波动时，司来吉兰会进一步加重峰值剂量运动障碍、幻觉和失眠等精神并发症以及直立性低血压。最近有报道称，与单独使用左旋多巴相比，司来吉兰和左旋多巴同时使用时死亡率增加，但对5项长期研究和4项独立研究的大型荟萃分析不支持这一结论。司来吉兰与其他药物合用通常耐受性良好。 However, when pethidine (meperidine) has been given to patients who are receiving selegiline therapy, severe adverse effects have been reported. Thus, the concomitant use of these drugs is not recommended. A low tyramine diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible MAO-A inhibitor, moclobemide. Several adverse effects have been reported when fluoxetine and selegiline have been used together. A recent survey revealed that the incidence of a true serotonin syndrome is, however, very low with this combination. Concomitant use of selegiline and other selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) like citalopram, which have generally less interactions than fluoxetine, seems to be well tolerated. Nevertheless, caution is advised when combining a SSRI or a tricyclic antidepressant and selegiline.

引用本文的药物库数据

药物靶点

药物	目标	种类	生物	药理作用	行动
优降宁	胺氧化酶[含黄素]B	蛋白质	人类	是的	抑制剂	细节
司立吉林	胺氧化酶[含黄素]B	蛋白质	人类	是的	抑制剂	细节